Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 4/2007

01-04-2007 | Meeting Report

International Meeting “Immunotherapy of Cancer: Challenges and Needs”

Authors: Maria Ferrantini, Imerio Capone, Francesco M. Marincola, Giorgio Parmiani, Filippo Belardelli

Published in: Cancer Immunology, Immunotherapy | Issue 4/2007

Login to get access

Abstract

The main aims of the international meeting “Immunotherapy of Cancer: Challenges and Needs” were to review the state of the art of cancer immunotherapy and to identify critical issues which deserve special attention for promoting progress of research in this field, with a particular focus on the perspectives of clinical research. Novel concepts and strategies for identifying, monitoring and predicting effective responses to cancer immunotherapy protocols were presented, focused on the use of adjuvants (CpG oligonucleotides) or cytokines (IFN-alpha) to enhance the efficacy of cancer vaccines. Moreover, the possible advantages of using different types of dendritic cells (for active immunization strategies) or T cells (for adoptive immunotherapy protocols) were debated. A consensus was achieved on the need for enhancing the efficacy of cancer vaccines or adoptive cell immunotherapy by combining these strategies with other anti-cancer treatments, including chemotherapy. Finally, initiatives for promoting clinical research by establishing a strategic cooperation in the field of cancer immunotherapy based on the active participation of all the relevant actors, including public institutions responsible of Public Health, National Cancer Institutes, industry, representatives of regulatory bodies, and patients’ organizations were proposed.
Appendix
Available only for authorised users
Literature
1.
go back to reference van Hall T, Wolpert EZ, van Veelen P et al (2006) Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 12:417–424PubMedCrossRef van Hall T, Wolpert EZ, van Veelen P et al (2006) Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 12:417–424PubMedCrossRef
2.
go back to reference Loukinov D, Ghochikyan A, Mkrtichyan M et al (2006) Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem 98:1037–1043PubMedCrossRef Loukinov D, Ghochikyan A, Mkrtichyan M et al (2006) Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem 98:1037–1043PubMedCrossRef
3.
go back to reference Bronte V, Zanovello P (2005) Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 5:641–654PubMedCrossRef Bronte V, Zanovello P (2005) Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 5:641–654PubMedCrossRef
4.
go back to reference Taieb J, Chaput N, Menard C et al (2006) A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 12:214–219PubMedCrossRef Taieb J, Chaput N, Menard C et al (2006) A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 12:214–219PubMedCrossRef
5.
go back to reference Speiser DE, Baumgaertner P, Barbey C et al (2006) A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol 177:1338–1348PubMed Speiser DE, Baumgaertner P, Barbey C et al (2006) A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol 177:1338–1348PubMed
6.
go back to reference Di Pucchio T, Pilla L, Capone I et al (2006) Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 66:4943–4951PubMedCrossRef Di Pucchio T, Pilla L, Capone I et al (2006) Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 66:4943–4951PubMedCrossRef
7.
go back to reference Gogas H, Ioannovich J, Dafni U et al (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709–718PubMedCrossRef Gogas H, Ioannovich J, Dafni U et al (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709–718PubMedCrossRef
8.
go back to reference Schadendorf D, Ugurel S, Schuler-Thurner B et al (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17:563PubMedCrossRef Schadendorf D, Ugurel S, Schuler-Thurner B et al (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17:563PubMedCrossRef
9.
go back to reference Huang J, Kerstann KW, Ahmadzadeh M et al (2006) Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol 176:7726–7735PubMed Huang J, Kerstann KW, Ahmadzadeh M et al (2006) Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol 176:7726–7735PubMed
10.
go back to reference Hoos A, Parmiani G, Hege K et al (2006) A new clinical development paradigm for cancer vaccines and related biologics. J Immunother (in press) Hoos A, Parmiani G, Hege K et al (2006) A new clinical development paradigm for cancer vaccines and related biologics. J Immunother (in press)
Metadata
Title
International Meeting “Immunotherapy of Cancer: Challenges and Needs”
Authors
Maria Ferrantini
Imerio Capone
Francesco M. Marincola
Giorgio Parmiani
Filippo Belardelli
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 4/2007
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-006-0251-6

Other articles of this Issue 4/2007

Cancer Immunology, Immunotherapy 4/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine